European life sciences and health technology companies have opened 2026 with a strong showing in private capital markets, as investors continue to back differentiated platforms across biotechnology and consumer health despite ongoing macroeconomic uncertainty.
In Switzerland, Basel-based TECregen has secured CHF10 million in seed financing to advance its pioneering work in thymus regeneration.
The round was led by the Boehringer Ingelheim Venture Fund, with participation from a broad syndicate that included LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds, the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank.
The funding will support the development of TECregen’s thymopoietic biologics, which are designed to rejuvenate thymic epithelial cells and restore immune function across ageing-related and immune-compromised indications.
Alongside the financing, TECregen strengthened its governance with the appointment of seasoned biotech executive Dr Bo Rode Hansen as Chair.
With prior leadership roles at Scandion Oncology, Genevant Sciences, Roche and Santaris Pharma, Hansen brings deep experience in scaling early stage science towards the clinic.
Investors highlighted the company’s potential to open new therapeutic avenues across immunology, oncology and rare diseases through targeted immune restoration.
In the UK, London-based Engitix announced a $25 million Series A extension, funded entirely by Netherton Investments on behalf of Mike Platt, founder and Managing Director of BlueCrest Capital Management.
The financing underscores continued investor confidence in platform-driven biotech models with strong data foundations.
Engitix is developing therapies that target the extracellular matrix (ECM), an area increasingly recognised as critical in cancer and fibrotic diseases.
Proceeds will be used to advance preclinical programmes in solid tumours and fibrosis, as well as to expand Engitix’s proprietary high-resolution ECM dataset, one of the largest of its kind.
The company’s strategy combines deep biological insight with data-led target discovery, aiming to deliver therapeutics that act precisely within diseased tissue microenvironments.
Meanwhile, Sweden’s Sigrid illustrates growing investor appetite for clinically validated consumer health technologies with clear commercial traction.
The Stockholm-based company raised $5 million, bringing total funding to approximately $27 million, to accelerate the US expansion of its non-systemic metabolic health platform.
Sigrid’s lead product, Glucose Stabiliser, has delivered more than threefold revenue growth during the past year through direct-to-consumer and physician channels.
The new capital will also support regulatory progress, including CE-mark approval for an over-the-counter medical device targeting weight reduction and blood sugar control, and expansion of Sigrid’s SiPore technology into adjacent markets such as oral care, veterinary health and food technology.
Collectively, the three financings highlight a resilient investment landscape for life sciences innovators across Europe, with capital flowing to companies that combine strong science, data-driven platforms and credible paths to commercialisation.